Target type: biologicalprocess
A homeostatic process involved in the maintenance of a steady state level of phosphate ions within a cell. [GOC:mah]
Intracellular phosphate ion homeostasis is a tightly regulated process crucial for maintaining cellular function. It involves the coordinated control of phosphate uptake, storage, utilization, and excretion. Phosphate is an essential component of numerous biological processes, including ATP production, DNA and RNA synthesis, signal transduction, and membrane integrity.
**Phosphate Uptake:** Cells acquire phosphate from the extracellular environment through specialized membrane transporters. These transporters include sodium-dependent phosphate co-transporters (NaPi), which utilize the sodium gradient to drive phosphate uptake, and organic phosphate transporters (PiT), which facilitate phosphate transport independently of sodium.
**Phosphate Storage:** Once inside the cell, phosphate is stored in the form of inorganic phosphate (Pi) or as organic phosphate esters, such as phosphocreatine and sugar phosphates. The intracellular Pi pool is regulated by various mechanisms, including the activity of phosphatases and kinases, which control the phosphorylation and dephosphorylation of cellular components.
**Phosphate Utilization:** Phosphate is utilized in a wide range of metabolic pathways. For example, in oxidative phosphorylation, phosphate is incorporated into ADP to generate ATP, the energy currency of the cell. Phosphate is also required for the synthesis of nucleic acids, phospholipids, and other essential biomolecules.
**Phosphate Excretion:** Excess phosphate is excreted from the cell through specialized membrane transporters. The mechanisms of phosphate excretion vary depending on the cell type and the physiological conditions.
**Regulation of Phosphate Homeostasis:**
* **Hormonal Regulation:** Parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) are key hormones that regulate phosphate homeostasis. PTH increases phosphate reabsorption in the kidneys, while FGF23 inhibits phosphate absorption in the intestines and promotes phosphate excretion in the kidneys.
* **Cellular Signaling:** Intracellular signaling pathways, such as the AMP-activated protein kinase (AMPK) pathway, can influence phosphate homeostasis by regulating the expression and activity of phosphate transporters and enzymes.
* **Metabolic Status:** The cellular energy status, as reflected by the ATP/ADP ratio, can influence phosphate homeostasis. For example, low ATP levels stimulate phosphate uptake and utilization.
**Disruption of Phosphate Homeostasis:**
* **Hypophosphatemia:** Low phosphate levels in the blood can lead to various disorders, including muscle weakness, bone disease, and impaired cell function.
* **Hyperphosphatemia:** Elevated phosphate levels in the blood can cause calcium deposition in soft tissues, leading to kidney stones and vascular calcification.
In summary, intracellular phosphate ion homeostasis is a complex process involving coordinated uptake, storage, utilization, and excretion of phosphate. It is tightly regulated by a variety of mechanisms to ensure adequate supply of phosphate for cellular processes while preventing harmful accumulation.'
"
Protein | Definition | Taxonomy |
---|---|---|
Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 | An ectonucleotide pyrophosphatase/phosphodiesterase family member 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P22413] | Homo sapiens (human) |
Sodium-dependent phosphate transport protein 2B | A sodium-dependent phosphate transport protein 2B that is encoded in the genome of human. [PRO:DNx, UniProtKB:O95436] | Homo sapiens (human) |
Na(+)/H(+) exchange regulatory cofactor NHE-RF1 | A Na(+)/H(+) exchange regulatory cofactor NHE-RF1 that is encoded in the genome of human. [PRO:CNA, UniProtKB:O14745] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
alpha,beta-methyleneadenosine 5'-triphosphate | alpha,beta-methyleneadenosine 5'-triphosphate: do not confuse with beta,gamma-methylene ATP; RN given refers to parent cpd | nucleoside triphosphate analogue | |
adenosine 5'-methylenediphosphate | nucleoside diphosphate analogue | ||
3'-o-(4-benzoyl)benzoyladenosine 5'-triphosphate | 3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate: purinergic receptors agonist; structure given in first source | purine ribonucleoside triphosphate | |
methylthio-adp | |||
Reactive blue 2 | anthraquinone | ||
fh535 | FH535: inhibits Wnt signaling | sulfonamide | |
2-methylthio-atp | 2-methylthio-ATP: purinergic receptors agonist; relaxes mammalian gut preparations; structure given in first source | ||
adenosine 5'-diphosphate 2',3'-dialdehyde | |||
arl-67156 | 6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP: an inhibitor of ecto-ATPase | ||
crizotinib | crizotinib : A 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine that has R configuration at the chiral centre. The active enantiomer, it acts as a kinase inhibitor and is used for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) Crizotinib: A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR (HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER. | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent; biomarker; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
pf-06463922 | lorlatinib : A cyclic ether that is 16,17-dihydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecin-15(10H)-one substituted by methyl groups at positions 2 and 10R, and by cyano, amino and fluoro groups at positions 3, 7 and 12 respectively. It is a small molecule inhibitor of ALK and ROS1 kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer. lorlatinib: inhibits both anaplastic lymphoma kinase and c-ros oncogene 1 (ROS1) protein | aminopyridine; aromatic ether; azamacrocycle; benzamides; cyclic ether; monofluorobenzenes; nitrile; organic heterotetracyclic compound; pyrazoles | antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |